The Impact of Statin Therapy on Outcomes in Lung Cancer Patients Receiving Immune Checkpoint Inhibitors: Insights from a Meta-Analysis

1

Lung cancer is a leading cause of cancer-related mortality, with immune checkpoint inhibitors (ICIs) improving survival in advanced cases.
2

Statins may enhance antitumor immune activity and have been studied for their potential benefits in lung cancer patients receiving ICIs.
3

This meta-analysis included 12 studies with 5,156 participants, showing statin use significantly improved overall survival (OS) and progression-free survival (PFS).
4

The survival advantage associated with statin use was significant in multivariate analyses but not in univariate analyses or larger studies.
5

Results suggest a need for caution in interpretation due to the retrospective nature of most studies, highlighting the need for prospective trials.

1